South Korea Continuous Renal Replacement Therapy Market

South Korea Continuous Renal Replacement Therapy Market Summary

As per Transpire Insight Analysis the South Korea Continuous Renal Replacement Therapy Market size is estimated at USD 37.7 Million in 2025 and is anticipated to reach USD 77.5 Million by 2033, growing at a CAGR of 9.41% from 2026 to 2033.

Continuous renal replacement therapy, CRRT, helps critically ill patients when their kidneys can’t safely handle fluid, electrolytes, and waste during acute sickness. In the real world, CRRT gives ICU teams a way to pull off fluid and solutes step by step, while keeping better hemodynamic stability than intermittent dialysis. Because of this, CRRT becomes especially relevant for severe AKI cases and those unstable ICU patients, you know when blood pressure just won’t behave.

In the past 3-5 years, the market has been moving toward more integrated CRRT platforms, with automated fluid governance, connectivity, and treatment-monitoring features that feel almost baked in. Baxter’s PrisMax is one example, it brings in EMR connectivity and analytics, and the more automated parts can cut down on treatment pauses and also reduce the nursing load, a kind of quieter workflow. The COVID-19 period meanwhile made it very clear how crucial resilient critical-care capacity really is. It also sped up focus on ICU renal-support infrastructure. Then South Korea’s 2025 clinical guideline adds extra support for selective CKRT use in severe AKI and hemodynamic instability. So, overall hospitals are steering toward higher-value systems that improve consistency, monitoring, and resource utilization, pushing market growth from USD 37.7 million in 2025 up to USD 77.5 million by 2033.

South Korea Continuous Renal Replacement Therapy Market Size & Forecast:

• South Korea Continuous Renal Replacement Therapy Market Size 2025: USD 37.7 Million
• Expected Market Value 2033: USD 77.5 Million
• Forecast CAGR: 9.41%
• Key Profile: Baxter International, Fresenius Medical Care, B. Braun, Nipro Corporation, Asahi Kasei Medical, Medtronic, Toray Medical, Nikkiso, JMS Co. Ltd., Cytiva, Infomed SA, NxStage Medical, Outset Medical, DaVita Inc., Cantel Medical

Key Market Insights

• The South Korea Continuous Renal Replacement Therapy Market is kinda shifting toward integrated devices, where the whole thing—therapy delivery, monitoring, connectivity, and workflow support—comes in one package, instead of separate components. 
• Market value is expected to climb from USD 37.7 million in 2025 up to about USD 77.5 million by 2033, and that also supports more investment in ICU renal-support systems, you know the kind designed for faster clinical response.
• CVVHDF is still a strategically key method for hard ICU scenarios because the combined convection and diffusion style gives flexible solute and fluid management, which matters when patients don’t really fit a neat pattern. 
• Hospitals are increasingly leaning on automated fluid-management functions, which cuts down on the manual touchpoints, and it helps clinical teams keep the prescribed treatment targets steady during long-running therapy sessions.
• South Korea’s 2025 CKRT guidance backs selective use for severe AKI and hemodynamic instability so the deployment stays evidence-based, rather than being used too broadly. 
• In the meantime Baxter, Fresenius Medical Care, B. Braun, Nipro, and Asahi Kasei Medical keep influencing competition through their equipment, consumables, and renal-care technology portfolios.
• Digital connectivity is becoming a stronger buying signal, since hospitals want better treatment recording, clinical oversight, and even program-level performance monitoring , not just day to day operation. 
• ICU use cases stay at the center, while areas like cardiac surgery, sepsis, multi-organ failure, and fluid-overload patients are expanding what the clinical market can actually reach.
• And AI research is moving away from general prediction ideas, toward more practical support such as dose assistance, filter-failure prediction, fluid management guidance, and anticoagulation monitoring tools, which sounds “small” but it’s pretty impactful in real workflows.

What are the Key Drivers, Restraints, and Opportunities in the South Korea Continuous Renal Replacement Therapy Market?

Driver: The main growth engine is kinda the expanding clinical use of CKRT in people with severe AKI, especially those who are hemodynamically unstable. South Korea’s 2025 evidence-based guideline already flags CKRT as a core renal-replacement choice, right next to intermittent hemodialysis, and it backs up selective use when hypotension, or arrhythmia shows up. With this kind of clinical placement, hospitals, especially tertiary centers and ICUs, tend to buy the equipment, because CRRT can do controlled fluid plus solute removal when standard dialysis is just too hard to tolerate. When treatment episodes keep stacking up, demand also repeats for machines hemofilters, bloodline sets , dialysis solutions, and replacement fluids.

Restraint: Still, high operational complexity is sort of a built in constraint. CRRT needs specialized machinery continuous observation, trained clinicians, vascular access, anticoagulation handling, and dependable consumables. Because of all that, the total cost of ownership climbs, and adoption becomes more difficult for facilities that don’t have mature ICU infrastructure. Training, staffing pressure, and learning-curve issues can slow down deployment, and it can also keep usage lower outside the big tertiary hospitals.

Opportunity: AI-enabled clinical decision support may open a forward route toward better CRRT value. Studies have shown potential for individualized dosing, filter-failure forecasting, smarter fluid control and anticoagulation assistance. A 2026 machine-learning report additionally mentioned strong predictive capability for personalized meropenem dosing in CRRT patients. That result suggests a feasible path toward treatment support tools that clinicians can actually use in day-to-day care.

What Has the Impact of Artificial Intelligence Been on the South Korea Continuous Renal Replacement Therapy Market?

Artificial intelligence is starting to influence CRRT, mostly via clinical decision support instead of any kind of fully autonomous machine work. Digital CRRT platforms already gather a lot of stuff—treatment parameters, circuit details, delivered dose, ultrafiltration rates, plus interruption information, and then those inputs can be used for analytics. Take Baxter's PrisMax, for example, it offers EMR connectivity along with analytics through its TrueVue platform, so clinicians can do an ongoing, continuous look at CRRT program performance. In practice, that kind of capability can cut down manual charting a bit and help teams spot when there were treatment pauses or when the care path drifts from the prescribed therapy.

Also, machine-learning research seems to be shifting toward predictive uses, rather than just descriptive summaries. The newer models can evaluate both patient data and machine data to help foresee filter failure, guide individualized dosing, support more careful fluid-management decisions, and even assist with anticoagulation monitoring. For instance, a 2026 study on meropenem dosing suggested that machine learning could beat a conventional pharmacokinetic model in external validation, which points toward personalized drug dosing during CRRT. Tools like that might raise treatment precision, and lower some interruptions that were avoidable, yet adoption is still kind of restricted because getting high quality, multimodal datasets is hard , they need harmonization, prospective validation, and then dependable clinical integration.

Key Market Trends

• Since 2021, hospitals have started putting more weight on a resilient ICU renal-support capacity, mainly because the whole pandemic thing really strained critical-care resources.
• Since 2025, Korean clinical guidance has gone further with selective CKRT use for severe AKI, plus for patients with hemodynamic instability.
• CRRT equipment has also moved away from mostly standalone pumping systems, toward integrated platforms that bring connectivity, analytics, and automated treatment functions into the same setup.
• The newer automated fluid-management features have cut down the manual workload , and they tend to keep things more consistent during those long running sessions in advanced ICU environments.
• CVVHDF has become kind of strategically important for tricky ICU situations, where you need convection and diffusion based solute clearance at the same time.
• And when hospitals buy, they’re thinking more about recurring consumables requirements , not just machine acquisition, so the reliability of the filter and bloodline supply is more visible than before.
• AI research has gone beyond pure theory, now it targets filter-failure prediction , dose optimization, fluid management, and decision support around anticoagulation.
• In 2026, machine-learning work showed strong predictive performance for individualized meropenem dosing during CRRT , which helps support more personalized critical-care pharmacotherapy.
• Tertiary hospitals and academic medical centers still lead the more sophisticated CRRT adoption, because advanced ICUs can sustain continuous monitoring and specialist staffing.
• Overall, competition strategies increasingly blend equipment , consumables, connectivity, analytics, and even clinical workflow support, rather than focusing only on the machine specifications.

South Korea Continuous Renal Replacement Therapy Market Segmentation

By Product Type:

CRRT machines are kind of the central hardware class and they deliver continuous blood purification for the severely ill patients who still need controlled renal support. Hemofilters take away uremic waste and remove excess fluid, and bloodline sets basically build the extracorporeal loop that links the patient with the machine. Dialysis solutions, plus replacement fluids help with diffusion and convection based therapy, so it becomes a repeating need for consumables. Catheters give vascular access, while tubing sets allow the circuit to be arranged and the fluids to actually move. Accessories then fit in to improve the setup safety and day to day operational convenience. Monitoring systems keep an eye on treatment parameters and patient related variables, which supports clinical supervision during these long sessions. Other products also exist, meaning supporting parts used across different CRRT setups. So overall, procurement is a mix, it’s both an initial equipment spend and then ongoing consumable purchasing across hospital critical-care services.

CRRT machines are usually the focus when budgets are discussed because machine capability strongly shapes treatment flexibility , automation, and staff workflow. Hemofilters, bloodline sets, dialysis solutions, and replacement fluids create repeat purchasing because each treatment run needs regular replacement of consumables. Catheters and tubing sets stay essential for maintaining safe circuit function, whereas accessories help with setup continuity and upkeep. Monitoring systems become even more important as hospitals try to improve visibility into how treatment is delivered and how fluid balance is tracking. Other products support niche requirements that vary across clinical contexts. Going forward product selection will likely lean toward more integrated systems that merge treatment delivery with monitoring, connectivity, and workflow-support capabilities.

By Modality:

CVVH basically relies on convection to get rid of solutes across a hemofilter, and it kind of needs replacement fluid so the overall volume stays on track . CVVHD instead leans on diffusion via dialysate, and it lets clinicians dial in clearance of smaller molecules in a fairly controlled way. Then CVVHDF merges both convection and diffusion, so it gives a wider clearance range, which can matter in those tougher critical-care situations . SCUF is more about supervised fluid takeoff, and it can help especially when patients have pronounced fluid overload. PIRRT is prolonged intermittent renal replacement, and it may work well for selected patients who need something gentler than standard intermittent hemodialysis. Hybrid therapy just combines the strategies depending on what the clinical team actually needs that day.

Continuous hemodialysis highlights diffusion, while continuous hemofiltration highlights convection based extraction. Combination therapy gives you the option to tailor renal support based on hemodynamic tolerance, the solute load, and fluid management priorities. Other modalities exist too , usually as specialized setups that are used for particular patient groups. Choosing the modality will depend on how stable the patient is, what the treatment targets are, what equipment is available , and the ICU protocols in place. In practice, CVVHDF and these combined approaches can allow flexible handling when multiple goals have to be addressed at the same time.

By End User:

Hospitals are basically the key end user bucket since CRRT really does lean on critical care infrastructure, ongoing specialist oversight , proper vascular access and continuous monitoring that has to stay steady. Specialty clinics can still deliver renal support for a subset of patients, provided they have the right clinical setup, resources, and some kind of reliable oversight. Dialysis centers mostly back up established renal replacement schedules, but the more involved continuous therapies tend to stay tied to critical care environments where the monitoring is already in place. ICUs drive a lot of the demand because severe AKI, sepsis, fluid overload, and multi organ failure show up often in the critically ill. Academic medical centers also play a major part, supporting advanced treatment tracks, clinical investigations and technology evaluation, which matters when protocols and devices evolve. Emergency care centers may need to start CRRT for unstable patients, especially when immediate kidney support is the whole point.

Research institutes help move things forward through technology development, clinical studies, and fine tuning of therapies. Ambulatory care centers take on less of the load, mainly because continuous extracorporeal treatment needs a level of supervision that is hard to maintain outside a dedicated unit. Military hospitals may use CRRT for critically ill patients too, when advanced renal support is required and logistics are managed. Other end users include particular healthcare facilities with adequate critical care capability, not just basic dialysis services. In practice , hospital and ICU use will stay central since CRRT delivery depends heavily on constant patient observation, trained personnel, and fast clinical response.

By Age Group:

Adults are usually seen as the broadest patient category for CRRT, mostly because acute kidney injury plus severe critical illness often shows up in adult ICU populations, and that’s where renal-support interventions are frequently needed. Pediatrics, on the other hand, tends to demand specialized equipment, dosing protocols, specific vascular-access choices, plus careful fluid-management approaches. Neonates bring yet another layer of technical requirements since their blood volume is very low and the treatment margin is narrow. Geriatric patients can also end up on CRRT when weakened physiological reserve meets acute kidney injury, cardiovascular instability, or a serious infection. Critical care patients are an important clinical grouping across different ages, since CRRT mainly supports people with significant systemic illness.

Trauma patients might need renal support after a major injury, during shock, or when complications develop after prolonged intensive care. Surgical patients can receive CRRT after complex procedures, especially when kidney function becomes unsettled and fluid balance is no longer steady. People with chronic kidney disease may also require continuous therapy if there’s an acute decline happening alongside severe illness. Acute kidney injury patients stay as a central treatment group because CRRT directly helps with fluid, electrolyte, and waste-management issues during critical illness. Other age or clinical categories exist too, but they’re more niche situations, and the therapy selection has to be customized for each case.

By Application:

Acute kidney injury is kind of the main use case, since CRRT gives a steady renal support option when people are critically ill and can’t handle fast fluid or solute removal very well. Sepsis care can also lead to CRRT because when severe infection shows up it may push the patient toward AKI, plus fluid imbalance, and even multi-organ dysfunction. When multi-organ failure is in play, the whole management gets pretty complicated, so renal support becomes only one piece of the wider intensive-care plan. Fluid overload counts as another major application too, because slower ultrafiltration can help with more controlled volume handling in patients who stay unstable. And for drug poisoning, some selected toxicology situations may need extracorporeal clearance, but only when the right substances are involved and the patient’s clinical situation allows this kind of treatment.

After cardiac surgery, CRRT can show up during recovery if postoperative AKI develops or if fluid balance goes sideways. Liver failure can create messy metabolic and fluid-management problems that may, at times, call for extracorporeal support. The intensive care unit is still the primary place for this treatment, mostly because CRRT needs continuous monitoring and specialist oversight, so it’s not really something that works well without that supervision. Burn care can create renal-support requirements after severe injury, shock, infection, or other fluid-management complications. Beyond these, there are other applications, like those specialized clinical moments where continuous extracorporeal therapy fits best as the renal-support approach.

What are the Key Use Cases Driving the South Korea Continuous Renal Replacement Therapy Market?

Acute kidney injury in critically ill patients is kind of the central use case, since CRRT allows a slower fluid and solute removal, which is useful when hemodynamic instability is going on. In South Korea , the 2025 CKRT guideline explicitly supports selective use for severe AKI and for those unstable patients too, so it really strengthens ICU adoption.

Sepsis, multi organ failure, and fluid overload are also getting wider attention inside hospital ICUs and academic medical centers. CRRT helps with controlled fluid regulation when severe systemic illness makes conventional intermittent dialysis hard to tolerate, and that’s why demand keeps rising across more complicated critical care pathways.

Drug poisoning and postoperative renal dysfunction are newer openings , especially for emergency care and cardiac surgery programs. AI supported dosing approaches and predictive tools may further broaden personalized CRRT use, as clinical validation keeps moving forward.

Which Regions are Driving the South Korea Continuous Renal Replacement Therapy Market Growth?

Seoul and the nearby capital region seem to be the strongest kind of demand hub, mostly because that area gathers the most tertiary hospitals and higher-level critical-care setups. By 2023, Seoul itself covered 14 of South Korea’s 45 tertiary hospitals, so it basically forms a tight foundation for nephrology, intensive care, and academic medicine, kind of all in one place. Then in the 2024-2026 tertiary-hospital reshuffle program, major hospitals are being pulled toward severe, urgent, or emergency workloads, and that kind of direction naturally backs up more advanced renal-support technology, including CRRT.

Meanwhile the southeastern medical belt, which stretches across Busan, Ulsan, and parts of Gyeongsang, works more through a wider web of regional tertiary hospitals rather than relying on Seoul’s heavy concentration of national academic centers. In the eastern Gyeongnam region, five tertiary hospitals were identified—Pusan National University Hospital, Dong-A University Hospital, Ulsan University Hospital, and Inje University Pusan Paik Hospital are among them. This gives the area a relatively steady base for critical-care treatments, so CRRT use can spread beyond the capital’s largest medical centers too.

The quickest growth, I’d expect, would happen across regional healthcare hubs outside the capital, since South Korea keeps reinforcing region-wide, whole essential-care networks. In 2024, the Ministry of Health and Welfare also named extra responsible regional and area-level medical institutions, bringing the overall national count to 17 regional and 55 local facilities. With this rebalancing of advanced-care capacity, CRRT suppliers get a chance to focus on hospitals that are upgrading their intensive-care capabilities, especially where imported equipment could be complemented by locally produced alternatives.

Who are the Key Players in the South Korea Continuous Renal Replacement Therapy Market and How Do They Compete?

Competition is pretty concentrated around big multinational renal-care outfits that already have the equipment, consumables, training, plus general hospital-support down pretty well. What really drives the race isn’t just the price of the equipment though. Technology, how dependable the treatment is, the recurring consumable supply, clinician training, and digital workflow integration tend to matter more, because CRRT, is more or less continuous supervision all the way through. The competitive structure is also moving, as South Korean manufacturers build domestic alternatives, which then cuts down dependence on imported critical-care dialysis equipment.

Vantive differentiates with an integrated CRRT approach plus digital support that’s wrapped around the PrisMax platform, with TrueVue connectivity and analytics as part of it. After the split from Baxter in February 2025, Vantive became its own kidney and vital-organ-therapy company backed by Carlyle, so the whole business has a dedicated investment structure meant for more innovation. Fresenius Medical Care shows up with multiFiltratePRO plus a wider renal-care portfolio, meaning hospitals can usually buy CRRT machines and dedicated CRRT fluids from the same supplier, rather than stitching together multiple pieces.

Nipro is taking a more complete dialysis strategy across Korea, instead of just chasing individual devices. In April 2025, Nipro renamed its Korean medical-device subsidiary to NIPRO MEDICAL KOREA, and said it plans to bring dialysis solutions and cleaning agents, while also expanding its market presence. Asahi Kasei Medical plays up blood-purification know how, including CUREFLO CRRT products, and PlasautoΣ technology. Meanwhile, Nipro has leverage from its broader hemofilter, tubing, catheter, and dialysis-device offering, which also translates into recurring-consumable strength.

Company List

• Baxter International
• Fresenius Medical Care
• B. Braun
• Nipro Corporation
• Asahi Kasei Medical
• Medtronic
• Toray Medical
• Nikkiso
• JMS Co. Ltd.
• Cytiva
• Infomed SA
• NxStage Medical
• Outset Medical
• DaVita Inc.
• Cantel Medical

Recent Development News

• "In February 2025, Vantive launched as a standalone vital organ therapy company following Carlyle's acquisition of Baxter's Kidney Care business. The separation gives the CRRT business an independent investment platform focused on kidney care, digital solutions, and vital-organ therapies.https://www.vantive.com/news/press-releases/baxter-kidney-care-now-vantive-new-standalone-vital-organ-therapy-company (Vantive)."
• "In April 2025, Nipro renamed its Korean medical-device subsidiary Nipro Dongduk Medical Corporation to NIPRO MEDICAL KOREA CORPORATION. The move strengthens Nipro's Korean brand presence and supports expansion into dialysis solutions and other renal-care products.https://www.nipro.co.jp/en/assets/document/newsrelease/250417.pdf (Nipro Corporation)."
• "In February 2026, Synopex increased investment in CRRT and hemodialysis-device development and production preparation. The company reported higher investment costs for CRRT and HD development and manufacturing preparation, supporting the localization of critical dialysis equipment in South Korea.https://kind.krx.co.kr/external/2026/02/09/001771/20260205001548/70443.htm (Korea Exchange)."

What Strategic Insights Define the Future of the South Korea Continuous Renal Replacement Therapy Market?

The market seems to be gradually but definitely moving toward higher-value CRRT systems that sort of merge dependable extracorporeal therapy with monitoring, connectivity, analytics, and workflow support. The driving thing here is not just patient volume, but the way severe-care activity is concentrating in tertiary hospitals, plus that policy shift toward stronger regional critical-care capability. There’s also a quieter risk that people don’t always flag early supplier concentration, because most hospitals still rely on imported machines and consumables while domestic options are still finding their footing, commercialization, and then scaling up. That can leave a gap for things like component shortages, regulatory hold-ups, or manufacturing disruptions.

Synopex’s localization program might tip the balance if domestic CRRT production gets to commercial scale and can show performance that’s clinically on par. Beyond that, there’s another emerging chance in predictive digital CRRT tools, especially models that anticipate membrane fouling and even possible treatment interruptions. Some recent research described a membrane-fouling machine learning approach with 77.6% sensitivity and 96.3% specificity, which suggests it could offer genuinely useful predictive support in practice. So market players should probably focus on partnerships with tertiary hospitals, localize the most critical consumables, and then build validated digital services along with the hardware, instead of pushing mainly on machine price.

South Korea Continuous Renal Replacement Therapy Market Report Segmentation

By Product Type
• CRRT Machines
• Hemofilters
• Bloodline Sets
• Dialysis Solutions
• Replacement Fluids
• Catheters
• Tubing Sets
• Accessories
• Monitoring Systems
• Others

By Modality
• CVVH
• CVVHD
• CVVHDF
• SCUF
• PIRRT
• Hybrid Therapy
• Continuous Hemodialysis
• Continuous Hemofiltration
• Combination Therapy
• Others

By End User
• Hospitals
• Specialty Clinics
• Dialysis Centers
• ICUs
• Academic Medical Centers
• Emergency Care Centers
• Research Institutes
• Ambulatory Care Centers
• Military Hospitals
• Others

By Age Group
• Adults
• Pediatrics
• Neonates
• Geriatrics
• Critical Care Patients
• Trauma Patients
• Surgical Patients
• Chronic Kidney Disease Patients
• Acute Kidney Injury Patients
• Others

By Application
• Acute Kidney Injury
• Sepsis Management
• Multi-Organ Failure
• Fluid Overload
• Drug Poisoning
• Cardiac Surgery Recovery
• Liver Failure
• Intensive Care
• Burn Care
• Others